Novartis Healthcare launches psoriasis treatment drug in India

Novartis Healthcare has launched secukinumab, used for the treatment of plaque psoriasis in adult patients, in India.
The company has launched the drug in the strength of 150 mg, for the treatment of moderate-to-severe plaque psoriasis in adult patients, Novartis Healthcare said in a statement.
Scapho (secukinumab) is an injectable medicine and has been approved by the Drug Controller General of India (DCGI).
Novartis India Country President Jawed Zia said: "This signifies an important turning point in the treatment of psoriasis in India. Patients in India, can now benefit from this treatment as it has the proven ability to offer clear or almost clear skin."

Secukinumab is approved in over 50 countries, including Japan, Switzerland, Australia, the US, Canada and European Union countries.